When will the KURVELO patents expire, and when will generic KURVELO be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	KURVELO	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	091408-001	Oct 17, 2012	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 30, 2026

KURVELO fundamentals and investment scenario: what drives demand, patent risk, and generic entry outcomes

KURVELO (levonorgestrel/ethinyl estradiol tablets; branded combined oral contraceptive, COCP) is a mature, high-competition women’s health franchise where investment returns hinge less on near-term clinical upside and more on (1) payer and formulary positioning, (2) manufacturing continuity for oral tablet supply, and (3) patent and exclusivity barriers that determine generic timing by dosage strength and marketing authorization. The opportunity is typically distribution-and-market-share driven, not platform driven, with regulatory exclusivity and Orange Book patent coverage controlling Paragraph IV risk windows more than “novel” drug attributes.

What patents protect Kurvelo (levonorgestrel/ethinyl estradiol) and how strong is the patent estate?

Featured snippet answer: KURVELO is a combination COCP. For investment screening, the controlling question is not “patents on contraception broadly,” but which Orange Book-listed patents cover Kurvelo-specific strengths, formulation, manufacturing, and method-of-use claims, plus whether those are tied to FDA approval dates and unexpired statutory exclusivities.

What patent families usually show up for COCPs like Kurvelo

For branded COCPs, patent estates tend to cluster around:

Formulation and composition claims (tablet composition, excipients, dissolution profile).
Manufacturing process claims (granulation, compression, coating, in-process controls).
Method-of-use claims (contraception regimen, dosing schedule).
Polymorph/solid-state control claims (less common for mature COCPs but can appear for specific composition work).
Device and packaging claims (rare to be Orange Book-driving, but can appear).
System/kit claims (sometimes listed if tied to the NDA).

How to read patent strength for an investment case

In mature generics-adjacent products, patent “strength” is often the practical strength reflected by:

Remaining term (time to expiration) on the latest-listed Orange Book patents.
Litigation history (whether challengers filed ANDAs and the outcomes).
Whether relevant patents are formulation vs method-of-use (method-of-use is often harder to avoid with standard COCP labeling if the use is obvious and the ANDA is carve-out capable).
Exclusivity “stacking,” where FDA exclusivities (if any remain) can delay generic approval even after patent expiry.

Because your request is an investment scenario tied to KURVELO specifically, the analysis below focuses on the controllable fundamentals investors use for mature COCPs: exclusivity and generic timing, pricing and gross margin dynamics, and supply-chain execution. The patent estate’s precise inventory and expiration dates must be taken from the FDA Orange Book for Kurvelo’s exact NDA and strength listings.

Investment implication

If Orange Book coverage is thin or already expired, KURVELO behaves like a typical mature branded COCP with rapid conversion pressure, so valuation is driven by:

retained differentiation (brand loyalty, payer contracts, rebate structure),
continuity of supply and lot release,
and the ability to defend market share even after generic proliferation.

If coverage remains meaningful on key formulation/process patents, the business case can underwrite a longer brand runway, but the upside is still largely share protection, not new demand creation.

When does Kurvelo lose exclusivity and what are the generic entry risks?

Featured snippet answer: For COCPs, the generic entry timeline is governed by the later of (1) Orange Book patent expiry for Kurvelo-specific claims and (2) any remaining FDA exclusivities tied to the Kurvelo NDA/supplement, with Paragraph IV challenges creating litigation-linked approval delays.

Exclusivity components that matter

For FDA-tied exclusivity and generic timing, the practical drivers are:

Patent expiry dates (Orange Book listed).
Any unexpired statutory exclusivities (5 years, 3 years, 7 years for new chemical entities do not apply to old COCP actives in typical cases, but 3-year exclusivity for certain changes can exist).
Pediatric exclusivity extension (adds 6 months to qualifying patents if triggered).
Orphan exclusivity (not applicable to COCPs).
505(b)(2) vs ANDA pathway (competitors file accordingly; timing impact depends on which type of application is used).

Paragraph IV and “at-risk” periods

For investors, generic timing risk is often mapped like this:

If a Paragraph IV ANDA is filed, it can trigger 180-day exclusivity for the first filer (if not forfeited).
Court outcomes can delay approval even if patents expire during litigation.
Settlement agreements can lock “design-around” timing, sometimes via agreed-upon launch dates or modified labels.

Commercial risk translation

If Kurvelo’s Orange Book protection is limited, the expected path is:

Increased generic substitution after brand price erosion.
Margin compression from rebate pressure and payer step edits.
Lower sensitivity to marketing spend, because switching becomes pharmacist- and PBM-driven.

What is the Orange Book status of Kurvelo (NDA listings, listed patents, and expiration dates)?

Featured snippet answer: The definitive investment-grade view is the Orange Book for Kurvelo’s exact NDA and strength presentations. Investors pull three fields: patent numbers, expiration dates, and whether a listing is tied to a method-of-use vs composition/formulation.

What your diligence should extract from the Orange Book

NDA number and all strengths (including “active ingredient + strength” presentation).
All listed patents with expiration dates.
Patent type (composition/formulation, process, method-of-use).
Whether patents are “withdrawn” or “reinstated” via NDA supplements.
Patent holder/assignee chain (useful for assessing enforcement capability and litigation posture).

How Orange Book coverage changes your scenario

Heavy multi-patent coverage across multiple strengths tends to slow generic entry and spread risk.
Sparse or single patents increase launch-likelihood risk because design-arounds or carve-outs are easier.

What generic entry risks exist for Kurvelo after patent expiry?

Featured snippet answer: After patent expiry, COCP markets usually see rapid generic substitution because multiple competitors can offer bioequivalent tablets with standard contraception indications.

What determines how fast price collapses

Even when generics can enter, speed of substitution depends on:

PBM formulary status and contract terms.
Pharmacy channel dynamics (mail-order vs retail).
Plan design (tier placement, prior authorization, quantity limits).
Brand rebate strategy and patient switching friction.

How investors model it

For mature COCP brands, a common modeling pattern is:

Launch of authorized generics or non-labeled generics reduces net price first.
Increased generic penetration compresses gross margin through rebates and distributor pricing.
Brand share stabilizes only if payer contracts favor it or if specific patient cohorts resist switching.

How does Kurvelo compare with other levonorgestrel/ethinyl estradiol oral contraceptives?

Featured snippet answer: In COCPs with shared active ingredients, differentiation typically comes from formulation-specific attributes and brand/payer contracts, not clinical superiority. Competitive pressure usually tracks the number of generic SKUs and how aggressively payers move to lower-cost options.

Competitive axes investors should track

Number of generic equivalents by strength.
Whether “preferred brand” status shifts among equivalent COCPs.
Rebates and formulary placement by PBM class.
Supply reliability (shortages for tablet presentations can temporarily support brand pricing).

Why this matters

If Kurvelo’s competitive set has multiple low-cost generics already, future growth depends on share defense rather than new patient acquisition.

What patent litigation affects Kurvelo and could delay generic approval?

Featured snippet answer: For investment decisions in COCPs, litigation matters mainly for whether it delays generic approval past scheduled patent expiry.

What to look for in litigation records

Paragraph IV ANDA complaints and their asserted patents.
Claim construction outcomes and whether patents survive.
Consent judgments and settlement terms, including agreed launch dates.
Whether “skinny label” or carve-outs were used to avoid method-of-use claims.

How to translate litigation outcomes

If courts dismiss asserted patents, generic launches typically proceed quickly after any appeal windows.
If settlement delays launch, investors should incorporate the settlement date as the practical next milestone, not just patent expiration.

What formulations are protected by patents for Kurvelo (tablet strengths, dosing regimens)?

Featured snippet answer: For COCPs, investors need strength-specific coverage because each strength can have different Orange Book patent links, even when the actives match.

Dose presentation risk

If multiple Kurvelo strengths exist:

Generic entry might be strength-by-strength, not uniform.
Patent lists can differ across strengths based on which supplements cover changes.

Manufacturing sensitivity

Even with generic entry permitted, shortage or quality problems can limit uptake. Kurvelo’s value can persist if supply remains reliable.

Which companies are challenging Kurvelo via ANDAs, and what does that imply for market timing?

Featured snippet answer: Challenge intensity (number of ANDAs, first-filer status, and timing of filings) predicts how quickly PBMs will refresh formularies.

Investment signal

Multiple parallel challenges usually shorten the “waiting time” to generic approvals.
A single early-filer can create a longer exclusivity-delayed window for the first generic entrant.
If entrants withdraw or forfeit exclusivity, approval timing can still shift.

What is Kurvelo’s FDA regulatory status and how does pathway affect exclusivity?

Featured snippet answer: Kurvelo’s regulatory status is determined by its NDA approval and any post-marketing supplements. Generic timing depends on whether competitors seek ANDAs (generics/bioequivalence) or 505(b)(2) pathways.

What investors should map

NDA approval date and any supplement history tied to changes that could affect exclusivity.
Whether the product is “line extension” vs original approval.
Whether the label is standard COCP contraception with no complex REMS requirements (COCPs generally do not have REMS, but labeling content drives method-of-use interpretation).

What do KURVELO revenue exposure and margin drivers look like under generic competition?

Featured snippet answer: For mature COCPs, generic competition typically compresses net price while the remaining value is the ability to retain share through payer contracts and to maintain supply without disruption.

Key operating metrics to underwrite

Net sales and net price (not gross) per strength.
Rebate intensity and payer mix (government vs commercial).
Gross margin trend as generic penetration increases.
Inventory management and lot-release timelines.
Field and market access spend relative to share retention.

Valuation framing investors use

If exclusivity is still meaningfully unexpired, valuation can be anchored to expected duration until generic substitution.
If exclusivity is near end, valuation shifts to cash flow survival and cost control rather than growth.

Key Takeaways

KURVELO is a mature COCP franchise where investment outcomes depend on Orange Book-driven generic timing and the ability to defend net price through payer contracting and supply reliability.
The decisive investor questions are: what Orange Book patents remain for each Kurvelo strength, whether any FDA exclusivities remain, and whether Paragraph IV litigation or settlements delay generic approval.
Generic entry risk is structurally high in COCPs because bioequivalent tablet substitution is straightforward; the main differentiators are contract outcomes and formulation/manufacturing execution.
In most scenarios, upside is limited to share and margin defense, not clinical expansion.

FAQs

How do Paragraph IV settlements change the expected Kurvelo generic launch date?
Which Kurvelo strengths are most exposed to early generic substitution based on Orange Book coverage?
Do method-of-use patents meaningfully delay generics for COCPs like Kurvelo, or are they typically avoided via labeling?
How should investors model net price erosion for branded COCPs after first generic approvals?
What supply-chain indicators best predict whether Kurvelo can maintain market share during generic transition?

References

U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.

KURVELO Drug Patent Profile

Which patents cover Kurvelo, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for KURVELO

US Patents and Regulatory Information for KURVELO